Eidos Therapeutics (EIDX) Weakness is Overdone - JPMorgan
Tweet
Share
E-mailGet Alerts EIDX Hot Sheet
Price: $122.21 --0%
Rating Summary:
1 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
1 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
JPMorgan analyst Anupam Rama maintains Overweight on Eidos Therapeutics (NASDAQ: EIDX).
The analyst believes the weakness in the equity is overdone and continues to believe AG10 has room for differentiation.
For an analyst ratings summary and ratings history on Eidos Therapeutics click here. For more ratings news on Eidos Therapeutics click here.
Shares of Eidos Therapeutics closed at $20.23 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades ASX Limited (ASX:AU) (ASXFY) to Neutral
- Kotak Upgrades Honasa Consumer Ltd (HONASA:IN) to Buy (1)
- Citizens Downgrades Accelerant Holdings (ARX) to Market Perform
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
